A case of new mutation in maturity-onset diabetes of the young type 3 (MODY 3) responsive to a low dose of sulphonylurea

Diabetes Research and Clinical Practice

Volumn 81, Issue 1, 2008, Pages

  Ješić, Maja D ^a   Sajić, Silvija ^a   Ješić, Miloš M ^a   Maringa, Monika ^a   Micić, Dragan ^a   Necić, Svetislav ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Serbia)

Author keywords

Children; MODY type 3; Sulphonylurea therapy

Indexed keywords

GLICLAZIDE; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; INSULIN GLARGINE; SULFONYLUREA;

ARTICLE; CASE REPORT; DOSE RESPONSE; FAMILY HISTORY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; HYPERGLYCEMIA; MATURITY ONSET DIABETES MELLITUS; MATURITY ONSET DIABETES OF THE YOUNG TYPE 3; MOTHER; SCHOOL CHILD; SINGLE DRUG DOSE;

CHILD; DIABETES MELLITUS, TYPE 2; FEMALE; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MUTATION; PREGNANCY; PREGNANCY COMPLICATIONS; SULFONYLUREA COMPOUNDS;

EID: 44649186218     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2008.03.005     Document Type: Article

References (10)

1. Fajans S., Bell G., and Polonsky K. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N. Engl. J. Med. 13 (2001) 971-980
2. Hatterslley A., Bruining J., Shield J., Njolstad P., and Donaghue K. The diagnosis and management of monogenic diabetes in children. Pediatr. Diabetes 7 (2006) 352-360
3. Hathout E.H., Cockburn B.N., Mace J.W., Sharkey J., Chen-Daniel J., and Bell G.I. A case of hepatocyte nuclear factor-1alpha diabetes-MODY3 masquerading as type 1 diabetes in a Mexican-American adolescent and responsive to low dose of sulfonylurea. Diabetes Care 22 (1999) 867-868
4. Barret G.T. Differential diagnosis of type 1 diabetes: which genetic syndromes need to be considered?. Pediatr. Diabetes 8 (2007) 15-23
5. Hatterslley A., and Pearson E. Minireview: pharmacogenetics and beyond the interreaction of therapeutic response, beta cell physiology, and genetics in diabetes. Endocrinology 147 (2006) 2657-2663
6. Brunerova L., Treslova L., Pruhova S., Vosahlo J., Broz J., Lebl J., et al. Glibenclamide instead of insulin: a new chance for MODY 3 type diabetes patients: case report. Vnitr. Lek. 52 (2006) 275-279
7. Jacobson-Dickman E., and Levitsky L. Oral agents in managing diabetes mellitus in children and adolescents. Pediatr. Clin. N. Am. 52 (2005) 1689-1703
8. Pearson E.R., Liddell W.G., Shepherd M., Corrall R.J., and Hattersley A.T. Sensitivity to sulphonylureas in patients with hepatocyte nucler factor 1 alpha gene mutations: evidence for pharmacogenetics in diabetes. Diabetic Med. 17 (2000) 543-545
9. Shepherd M., Pearson E.R., Houghton J., Salt G., Ellard S., and Hattersley A.T. No deterioration in glycemic control in HNF-1alpha maturity-onset diabetes of the young following transfer from long-term insulin to sulphonylureas. Diabetes Care 26 (2003) 3191-3192
10. Pearson E.R., Liddell W.G., Shepherd M., Corrall R.J., and Hattersley A.T. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetes. Diabetic Med. 17 (2000) 543-545